Lund, Sweden - December 30, 2020 - BioInvent International AB (publ) (BINV) today announced that the company's total number of shares as per December 30, 2020 amounts to 39,376,096 shares, corresponding to an equal number of votes.

The change in the number of shares and votes results from the directed issue of 29,395,311 shares (before the reverse share split) to CASI Pharmaceuticals, Inc. announced on October 27, 2020 and approved by the General Meeting on November 27, 2020 and the reverse share split of the company's shares, whereby twenty-five (25) existing shares were consolidated into one (1) new share (Sw. sammanläggning 1:25), resolved by the General Meeting on November 27, 2020. Both the directed issue and the reverse share split has been carried out during December, 2020.

   
About BioInvent
BioInvent International AB (publ) (OMXS: BINV) is a clinical stage company that discovers and develops novel and first-in-class immuno-modulatory antibodies for cancer therapies, with four programs in clinical development. The Company's validated, proprietary F.I.R.S.T^TM technology platform simultaneously identifies both targets and the antibodies that bind to them, generating many promising new drug candidates to fuel the Company's own clinical development pipeline or for additional licensing and partnering.

The Company generates revenues from research collaborations and license agreements with multiple top-tier pharmaceutical companies, as well as from producing antibodies for third parties in the Company's fully integrated manufacturing unit. More information is available at www.bioinvent.com.

This information is information that BioInvent International AB is obliged to make public pursuant to the Financial Instruments Trading Act. The information was submitted for publication at 11.00 a.m. CET on December 30, 2020.